Cargando…
Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice
The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM)...
Autores principales: | Higuchi, Takashi, Oshiro, Hiromichi, Zhang, Zhiying, Miyake, Kentaro, Sugisawa, Norihiko, Katsuya, Yuki, Yamamoto, Norio, Hayashi, Katsuhiro, Kimura, Hiroaki, Miwa, Shinji, Igarashi, Kentaro, Zhao, Ming, Bouvet, Michael, Singh, Shree Ram, Tsuchiya, Hiroyuki, Hoffman, Robert M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393699/ https://www.ncbi.nlm.nih.gov/pubmed/30807997 http://dx.doi.org/10.1016/j.tranon.2019.01.007 |
Ejemplares similares
-
The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model
por: Higuchi, Takashi, et al.
Publicado: (2019) -
Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival
por: Higuchi, Takashi, et al.
Publicado: (2020) -
Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model
por: Igarashi, Kentaro, et al.
Publicado: (2017) -
A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatinum and doxorubicin in a patient-derived orthotopic xenograft (PDOX)
por: Igarashi, Kentaro, et al.
Publicado: (2017) -
An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model
por: Oshiro, Hiromichi, et al.
Publicado: (2021)